Improving solubility and pharmacokinetics of meloxicam via multiple-component crystal formation

Molecular Pharmaceutics

Volumn 9, Issue 7, 2012, Pages 2094-2102

  Weyna, David R ^a   Cheney, Miranda L ^a   Shan, Ning ^a   Hanna, Mazen ^a   Zaworotko, Michael J ^b   Sava, Vasyl ^c   Song, Shijie ^c   Sanchez Ramos, Juan R ^c  

^a Thar Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

dissolution; meloxicam; multiple component crystal; pharmaceutical cocrystal; pharmacokinetics; solubility

Indexed keywords

CARBOXYLIC ACID; MELOXICAM; N [4 [6 [4 (TRIFLUOROMETHYL)PHENYL] 4 PYRIMIDINYLOXY]BENZOTHIAZOL 2 YL]ACETAMIDE;

ACIDITY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG ABSORPTION; DRUG MECHANISM; DRUG SOLUBILITY; NONHUMAN; PRIORITY JOURNAL; RAT; SUSPENSION;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CARBOXYLIC ACIDS; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; HYDROGEN-ION CONCENTRATION; MALE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; THIAZINES; THIAZOLES;

EID: 84863333774     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300169c     Document Type: Article

References (51)

1. Allen, L. V.; Popovich, N. G.; Ansel, H. C. Ansel's pharmaceutical dosage forms and drug delivery systems; Lippincott Williams and Wilkins: Baltimore, MD, 2005.
2. Tozer, T. N.; Rowland, M. Introduction to Pharmacokinetics and Phamacodynamics: The Quantitative Basis of Drug Therapy; Lippincott Williams & Wilkins: Baltimore, MD, 2006.
3. Amidon, G. L.; Lennernäs, H.; Shah, V. P.; Crison, J. R. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability Pharm. Res. 1995, 12, 413
4. Thayer, A. M. Finding Solutions Chem. Eng. News 2010, 88 (22) 13
5. Dublin, C. H. Formulation Strategies for Poorly Soluble Drugs Drug Delivery Technol. 2006, 6, 34
6. Abraham, D. J.; Rotella, D. P. Burger's Medicinal Chemistry, Drug Discovery and Development, 7 th ed.; Wiley: Hoboken, NJ, 2010; Vol. 8.
7. Chen, H.; Khemtong, C.; Yang, X.; Chang, X.; Gao, J. Nanonization Strategies for Poorly Water Soluble Drugs Drug Discovery Today 2011, 16, 354
8. Vemula, V. R.; Lagishetty, V.; Lingala, S. Solubility Enhancement Techniques Int. J. Pharm. Sci. Rev. Res. 2010, 5, 41
9. Berge, S. M.; Bighley, L. D.; Monkhouse, D. C. Pharmaceutical Salts J. Pharm. Sci. 1977, 66, 1
10. Pudipeddi, M.; Serajuddin, A. T. M. Trends in solubility of polymorphs J. Pharm. Sci. 2005, 94, 929
11. Roche Naprosyn® and Anaprox® Medication Guide.
12. Stahl, P. H.; Wermuth, C. G. Handbook of Pharmaceutical Salts: Properties, Selection, and Use; WILEY-VCH: Zurich, 2002.
13. Davis, M. E.; Brewster, M. E. Cyclodextrin-based pharmaceutics: Past, present and future Nat. Rev. Drug Discovery 2004, 3, 1023
14. Vishweshwar, P.; McMahon, J. A.; Bis, J. A.; Zaworotko, M. J. Pharmaceutical co-crystal J. Pharm. Sci. 2006, 95, 499
15. Almarsson, O.; Zaworotko, M. J. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? Chem. Commun. 2004, 1889
16. Shan, N.; Zaworotko, M. J. The role of cocrystals in pharmaceutical science Drug Discovery Today 2008, 13, 440
17. Bak, A.; Gore, A.; Yanez, E.; Stanton, M.; Tufekcic, S.; Syed, R.; Akrami, A.; Rose, M.; Surapaneni, S.; Bostick, T.; King, A.; Neervannan, S.; Ostovic, D.; Koparkar, A. The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics J. Pharm. Sci. 2008, 97, 3942
18. Cheney, M. L.; Shan, N.; Healey, E. R.; Hanna, M.; Wojtas, L.; Zaworotko, M. J.; Sava, V.; Song, S.; Sanchez-Ramos, J. R. Effects of Crystal Form on Solubility and Pharmacokinetics: A Crystal Engineering Case Study of Lamotrigine Cryst. Growth Des. 2010, 10, 394
19. Hickey, M. B.; Peterson, M. L.; Scoppettuolo, L. A.; Morrisette, S. L.; Vetter, A.; Guzman, H.; Remenar, J. F.; Zhang, Z.; Tawa, M. D.; Haley, S.; Zaworotko, M. J.; Almarsson, Ö. Performance comparison of a co-crystal of carbamazepine with marketed product Eur. J. Pharm. Biopharm. 2007, 67, 112
20. Remenar, J. F.; Morissette, S. L.; Peterson, M. L.; Moulton, B.; MacPhee, J. M.; Guzman, H. R.; Almarsson, Ö. Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids J. Am. Chem. Soc. 2003, 125, 8456
21. Stanton, M. K.; Kelly, R. C.; Colletti, A.; Langley, M.; Munson, E. J.; Peterson, M. L.; Roberts, J.; Wells, M. Improved pharmacokinetics of AMG 517 through co-crystallization part 2: Analysis of 12 carboxylic acid co-crystals J. Pharm. Sci. 2011, 100, 2734
22. Cheney, M. L.; Weyna, D. R.; Shan, N.; Hanna, M.; Wojtas, L.; Zaworotko, M. J. Coformer Selection in Pharmaceutical Cocrystal Development: a Case Study of a Meloxicam Aspirin Cocrystal That Exhibits Enhanced Solubility and Pharmacokinetics J. Pharm. Sci. 2011, 100, 2172
23. Babu, N. J.; Nangia, A. Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals Cryst. Growth Des. 2011, 11, 2662
24. Schultheiss, N.; Newman, A. Pharmaceutical Cocrystals and Their Physicochemical Properties Cryst. Growth Des. 2009, 9, 2950
25. Weyna, D. R.; Cheney, M. L.; Shan, N.; Hanna, M.; Wojtas, L.; Zaworotko, M. J. Crystal engineering of multiple-component organic solids: Pharmaceutical cocrystals of tadalafil with persistent hydrogen bonding motifs CrystEngComm 2012, 14, 2377
26. McNamara, D. P.; Childs, S. L.; Giordano, J.; Iarriccio, A.; Cassidy, J.; Shet, M. S.; Mannion, R.; O'Donnell, E.; Park, A. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API Pharm. Res. 2006, 23, 1888
27. Stanton, M. K.; Bak, A. Physicochemical properties of pharmaceutical co-crystals: A case study of ten AMG 517 co-crystals Cryst. Growth Des. 2008, 8, 3856
28. Uppoor, V. R. S. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations J. Controlled Release 2001, 72, 127
29. Ahmed, M.; Khanna, D.; Furst, D. E. Meloxicam in rheumatoid arthritis Expert Opin. 2005, 1, 739
30. Thompson, J. P.; Sharpe, P.; Kiani, S.; Owen-Smith, O. Effect of meloxicam on postoperative pain after abdominal hysterectomy Br. J. Anaesth. 2000, 84, 151
31. Roughan, J. V.; Flecknell, P. A. Evaluation of a short duration behaviour-based post-operative pain scoring system in rats Eur. J. Pain 2003, 7, 397
32. Engelhardt, G.; Homma, D.; Schlegel, K.; Utzmann, R.; Schnitzler, C. Antiinflammatory, Analgesic, Antipyretic and Related Properties of Meloxicam, a New Nonsteroidal Antiinflammatory Agent with Favorable Gastrointestinal Tolerance Inflammation Res. 1995, 44, 423
33. Seedher, N.; Bhatia, S. Solubility Enhancement of Cox-2 Inhibitors Using Various Solvent Systems. AAPS PharmSciTech 2003, 4, Article 33.
34. Luger, P.; Daneck, K.; Engel, W.; Trummlitz, G.; Wagner, K. Structure and physicochemical properties of meloxicam, a new NSAID Eur. J. Pharm. Sci. 1996, 4, 175
35. Coppi, L.; Sanmarti, M. B.; Clavo, M. C. Crystalline Forms of Meloxicam and Processes for Thier Preparation and Interconversion. US 6,967,248 B2, 2005.
36. Davies, N. M.; Skjodt, N. M. Clinical Pharmacokinetics of Meloxicam Clin. Pharmacokinet. 1999, 36, 115
37. Cheung, R.; Krishnaswami, S.; Kowalski, K. Analgesic efficacy of celecoxib in postoperative oral surgery pain: A single-dose, two-center, randomized, double-blind, active- and placebo-controlled study Clin. Ther. 2007, 29, 2498
38. Malmstrom, K. K., P.; Coughlin, H.; Desjardins, P. J. A Randomized, Double-Blind, Parallel-Group Study Comparing the Analgesic Effect of Etoricoxib to Placebo, Naproxen Sodium, and Acetaminophen With Codeine Using the Dental Impaction Pain Model Clin. J. Pain 2004, 20, 147
39. Ghorab, M. M.; Abdel-Salam, H. M.; El-Sayad, M. A.; Mekhel, M. M. Tablet formulation containing meloxicam and beta-cyclodextrin: Mechanical characterization and Bioavailability evaluation AAPS PharmSciTech 2004, 5
40. Defazio, S.; Cini, R. Synthesis, X-ray structure and molecular modelling analysis of cobalt(II), nickel(II), zinc(II) and cadmium(II) complexes of the widely used anti-inflammatory drug meloxicam J. Chem. Soc., Dalton Trans. 2002, 1888
41. Han, H. K.; Choi, H. K. Improved absorption of meloxicam via salt formation with ethanolamines Eur. J. Pharm. Biopharm. 2007, 65, 99
42. Bock, T.; Saegmueller, P.; Sieger, P.; Tuerck, D. Meloxicam for Oral Administration. US 6,869,948 B1, 2005.
43. Struengmann, A.; Freudensprung, B.; Klokkers, K. New Pharmaceutical Compositions of Meloxicam with Improved Solubility and Bioavailability. WO 99/09988 A1, 1999.
44. Cheney, M. L.; Weyna, D. R.; Shan, N.; Hanna, M.; Wojtas, L.; Zaworotko, M. J. Supramolecular Architectures of Meloxicam Carboxylic Acid Cocrystals, a Crystal Engineering Case Study Cryst. Growth Des. 2010, 10, 4401
45. Tiekink, E. R. T.; Vittal, J.; Zaworotko, M. Organic Crystal Engineering: Frontiers in Crystal Engineering; John Wiley & Sons, Ltd.: Great Britain, 2010.
46. Aakeröy, C. B.; Forbes, S.; Desper, J. Using Cocrystals To Systematically Modulate Aqueous Solubility and Melting Behavior of an Anticancer Drug J. Am. Chem. Soc. 2009, 131, 17048
47. Black, S. N.; Collier, E. A.; Davey, R. J.; Roberts, R. J. Structure, solubility, screening, and synthesis of molecular salts J. Pharm. Sci. 2007, 96, 1053
48. Thomas, E.; Rubino, J. Solubility, melting point and salting-out relationships in a group of secondary amine hydrochloride salts Int. J. Pharm. 1996, 130, 179
49. Good, D. J.; Rodríguez-Hornedo, N. Solubility Advantage of Pharmaceutical Cocrystals Cryst. Growth Des. 2009, 9, 2252
50. Tumanov, N. A.; Myz, S. A.; Shakhtshneider, T. P.; Boldyreva, E. V. Are meloxicam dimers really the structure-forming units in the 'meloxicam-carboxylic acid' co-crystals family? Relation between crystal structures and dissolution behaviour CrystEngComm 2012, 14, 305-313
51. Auvinet, B.; Ziller, R.; Appelboom, T.; Velicitat, P. Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients with acute sciatica Clin. Ther. 1995, 17, 1078